Pain interference, neuropathic-like symptoms, pain intensity, and symptoms of central sensitization negatively impact individual’s disability after Chikungunya fever: cross-sectional study
Interferência da dor, sintomas do tipo neuropático, intensidade da dor e sintomas de sensibilização central afetam negativamente a capacidade funcional dos indivíduos após a febre Chicungunha: estudo transversal
Paula Renata Conceição de Oliveira Dias; Juliana Valentim Bittencourt; Jéssica Pinto Martins do Rio; Felipe José Jandre dos Reis; Laura Alice Santos de Oliveira; Leandro Alberto Calazans Nogueira
Abstract
BACKGROUND AND OBJECTIVES: Particular pain features, such as pain interference, neuropathic-like symptoms, and central sensitization (CS) symptoms may be present in patients with Chikungunya fever and lead to functional limitations. The present study aimed to assess the association between pain characteristics and the disability in participants affected by Chikungunya fever in the chronic phase.
METHODS: A cross-sectional study was conducted with 36 participants who filled out a sociodemographic, pain characteristics (pain interference – Brief Pain Inventory, neuropathic-like symptoms – PainDETECT Questionnaire, and CS-related signs and symptoms – Central Sensitization Inventory) and disability (Health Assessment Questionnaire) questionnaires. The Spearman correlation test (rho) verified the relationship between the outcomes.
RESULTS: Most of the participants were female (77%), with a mean age of 43 years. Twenty-seven (75%) participants presented nociceptive pain and 11 (30%) had central sensitization symptoms. There was a high positive correlation between the presence of neuropathic-like symptoms and disability (rho=0.71; p<0.001) and pain intensity and disability (rho=0.76; p<0.001). A moderate positive correlation was found between the central sensitization symptoms and disability (rho=0.51; p=0.002). Moreover, there is a low positive correlation between pain interference in an individual’s life and disability (rho=0.34; p=0.041).
CONCLUSION: Patients in chronic phase of Chikungunya fever revealed mild pain intensity and predominance of nociceptive pain. Pain interference, neuropathic-like symptoms, and central sensitization symptoms negatively impact individual’s disability after Chikungunya fever.
Keywords
Resumo
JUSTIFICATIVA E OBJETIVOS: Características particulares da dor, como interferência da dor, sintomas do tipo neuropático e sintomas de sensibilização central (SC), podem estar presentes em pacientes com febre Chicungunha e levar a limitações funcionais. O presente estudo teve como objetivo avaliar a correlação entre as características da dor e a capacidade funcional em participantes acometidos pela febre Chicungunha na fase crônica.
MÉTODOS: Foi realizado um estudo transversal com 36 participantes que preencheram questionários sociodemográficos, de características de dor (interferência da dor – Inventário Breve de Dor, sintomas do tipo neuropático – questionário PainDETECT, e sinais e sintomas relacionados à SC – Inventário de Sensibilização Central) e de capacidade funcional (Health Assessment Questionnaire). O teste de correlação de Spearman (rho) verificou a relação entre os desfechos.
RESULTADOS: A maioria dos participantes era do sexo feminino (77%), com média de idade de 43 anos. Vinte e sete (75%) participantes apresentaram dor nociceptiva e 11 (30%) apresentaram sintomas de sensibilização central. Houve alta correlação positiva entre a presença de sintomas do tipo neuropático e capacidade funcional (rho=0,71; p<0,001) e intensidade da dor e capacidade funcional (rho=0,76; p<0,001). Foi encontrada uma correlação positiva moderada entre os sintomas de sensibilização central e a capacidade funcional (rho=0,51; p=0,002). Além disso, há uma correlação positiva baixa entre a interferência da dor na vida do indivíduo e a capacidade funcional (rho=0,34; p=0,041).
CONCLUSÃO: Pacientes em fase crônica da febre Chicungunha apresentaram intensidade de dor leve e predominância de dor nociceptiva. A interferência da dor, os sintomas do tipo neuropático e os sintomas de sensibilização central afetam negativamente a capacidade funcional do indivíduo após a febre Chicungunha.
Palavras-chave
References
1 Amdekar S, Parashar D, Alagarasu K. Chikungunya virus-induced arthritis: role of host and viral factors in the pathogenesis. Viral Immunol. 2017;30(10):691-702.
2 Burt FJ, Chen W, Miner JJ, Lenschow DJ, Merits A, Schnettler E, Kohl A, Rudd PA, Taylor A, Herrero LJ, Zaid A, Ng LFP, Mahalingam S. Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen. Lancet Infect Dis. 2017;17(4):e107-e117.
3 Saúde. Monitoramento dos casos de Arboviroses urbanas transmitidas pelo Aedes (dengue, chikungunya e Zika). Bol Epidemiológico Arboviroses. 2021;51(24):1-13.
4 Schilte C, Staikowsky F, Couderc T, Madec Y, Carpentier F, Kassab S, Albert ML, Lecuit M, Michault A. Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study. PLoS Negl Trop Dis. 2013;7(3):e2137.
5 Tritsch SR, Encinales L, Pachco N, Cadena A, Cure C, McMahon E, Watson H, Porras Ramirez A, Mendoza AR, Li G, Khurana K, Jaller-Raad JJ, Castillo SM, Barrios Taborda O, Jaller-Char A, Echavez LA, Jiménez D, Gonzalez Coba A, Alarcon Gomez M, Ariza Orozco D, Bravo E, Martinez V, Guerra B, Simon G, Firestein GS, Chang AY. Chronic Joint Pain 3 Years after Chikungunya Virus Infection Largely Characterized by Relapsing-remitting Symptoms. J Rheumatol. 2020;47(8):1267-74.
6 Marques CDL, Duarte ALBP, Ranzolin A, Dantas AT, Cavalcanti NG, Gonçalves RSG, et al. Recomendações da Sociedade Brasileira de Reumatologia para diagnóstico e tratamento da febre chikungunya. Parte 1-Diagnóstico e situações especiais. Rev Bras Reumatol. 2017;57:(S2):S421-S437.
7 Shraim MA, Massé-Alarie H, Hall LM, Hodges PW. Systematic review and synthesis of mechanism-based classification systems for pain experienced in the musculoskeletal system. Clin J Pain. 2020;36(10):793-812.
8 Merskey, H. and Bogduk N. IASP Terminology. IASP. 2017. 209-14p.
9 Fontes AP, Fernandes AA, Botelho MA. Funcionalidade e incapacidade: aspectos conceptuais, estruturais e de aplicaão da Classificaão Internacional de Funcionalidade, Incapacidade e Saúde (CIF). Rev Port Saude Publica. 2010;28(2):171-8.
10 Santos A. Fiabilidade e Validade de Constructo da Pain DETECT Questionnaire. Instituto Politécnico de Satúbal. Escola Superior de Saúde. Instituto Politécnico de Setúbal. Escola Superior de Saúde; 2017.
11 de Souza CG, da Costa JF, de Sousa Dantas D, de Abreu Freitas RP, Lopes JM, Okano AH. Evaluation of pain, functional capacity and kinesiophobia in women in the chronic stage of chikungunya virus infection: a cross-sectional study in northeastern Brazil. Acta Trop. 2019;199:104853.
12 Cerqueira HML, Ribeiro IB, Cerqueira EM, Lima MM, Lima JBO, Alcantara Júnior LC, Lima MAO, Rios MLA, Falcão MB, Cunha RV. Repercussões na qualidade de vida de indivíduos com artralgia crônica póschikungunya. Soc Bras Med Trop. 2018. 1 p. pôster.
13 Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies. Bull World Health Organ. 2007;85(11):867-72.
14 Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 1983;17(2):197-210.
15 Freynhagen R, Baron R, Gockel U, Tölle TR. Pain DETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22(10):1911-20.
16 Rio JPMD, Bittencourt JV, Corrêa LA, Freynhagen R, Reis FJJD, Melo TB, Galace D, Nogueira LAC. Cross-cultural adaptation of the painDETECT questionnaire into Brazilian Portuguese. Braz J Anesthesiol. 2022;72(1):44-8
17 Mayer TG, Neblett R, Cohen H, Howard KJ, Choi YH, Williams MJ, Perez Y, Gatchel RJ. The development and psychometric validation of the central sensitization inventory. Pain Pract. 2012;12(4):276-85.
18 Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes. 2003;1:20.
19 Poquet N, Lin C. The Brief Pain Inventory (BPI). J Physiother. 2016;62(1):52.
20 Ferreira KA, Teixeira MJ, Mendonza TR, Cleeland CS. Validation of brief pain inventory to Brazilian patients with pain. Support Care Cancer. 2011;19(4):505-11.
21 Freynhagen R, Tölle TR, Gockel U, Baron R. The painDETECT project - Far more than a screening tool on neuropathic pain. Curr Med Res Opin. 2016;32(6):1033-57.
22 Neblett R, Hartzell MM, Mayer TG, Cohen H, Gatchel RJ. Establishing clinically relevant severity levels for the central sensitization inventory. Pain Pract. 2017;17(2):166-75.
23 Neblett R, Hartzell MM, Cohen H, Mayer TG, Williams M, Choi YH, Gatchel RJ. Ability of the central sensitization inventory to identify central sensitivity syndromes in an outpatient chronic pain sample. Clin J Pain. 2015;31(4):323-32.
24 Tanaka K, Murata S, Nishigami T, Mibu A, Manfuku M, Shinohara Y, Tanabe A, Ono R. The central sensitization inventory predict pain-related disability for musculoskeletal disorders in the primary care setting. Eur J Pain. 2019;23(9):1640-8.
25 Scerbo T, Colasurdo J, Dunn S, Unger J, Nijs J, Cook C. Measurement properties of the central sensitization inventory: a systematic review. Pain Pract. 2018;18(4):544-54.
26 Caumo W, Antunes LC, Elkfury JL, Herbstrith EG, Sipmann RB, Souza A, Torres IL, Souza Dos Santos V, Neblett R. The central sensitization inventory validated and adapted for a Brazilian population: Psychometric properties and its relationship with brain-derived neurotrophic factor. J Pain Res. 2017;10:2109-22.
27 Ferraz MB. Tradução para o português e validação do questionário para avaliar a capacidade funcional” Stanford Health Assessment Questionaire”. 1990.
28 Hinkle DE, Wiersma W, Jurs SG. Applied statistics for the behavioral sciences. Boston, Mass. [London]: Houghton Mifflin [Hi Marketing] (distributor); 2003.
29 Bittencourt JV, Bezerra MC, Pina MR, Reis FJJ, de Sá Ferreira A, Nogueira LAC. Use of the painDETECT to discriminate musculoskeletal pain phenotypes. Arch Physiother. 2022;12(1):1-8.
30 Amaral JK, Bilsborrow JB, Schoen RT. Brief report: the disability of chronic chikungunya arthritis. Clin Rheumatol. 2019;38(7):2011-4.
31 de Andrade DC, Jean S, Clavelou P, Dallel R, Bouhassira D. Chronic pain associated with the Chikungunya Fever: long lasting burden of an acute illness. BMC Infect Dis. 2010;10:31.
32 Benjamanukul S, Osiri M, Chansaenroj J, Chirathaworn C, Poovorawan Y. Rheumatic manifestations of Chikungunya virus infection: prevalence, patterns, and enthesitis. PLoS One. 2021;16(4):e0249867.
33 Fingleton C, Smart K, Moloney N, Fullen BM, Doody C. Pain sensitization in people with knee osteoarthritis: A systematic review and meta-analysis. Osteoarthr Cartil. 2015;23(7):1043-56.
34 Rahim AA, Thekkekara RJ, Bina T, Paul BJ. Disability with persistent pain following an epidemic of chikungunya in rural South India. J Rheumatol. 2016;43(2):440-4.
35 Watson H, Nogueira-Hayd RL, Rodrigues-Moreno M, Naveca F, Calusi G, Suchowiecki K, Firesteins GC, Simon G. Tender and swollen joint counts are poorly associated with disability in chikungunya arthritis compared to rheumatoid arthritis. Sci Rep. 2021;11(1):18578.
Submitted date:
03/14/2023
Accepted date:
05/31/2023
Facebook
Google+
Twitter
LinkedIn
Mendeley
Email